about
Assessing chemokine co-receptor usage in HIVNeutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesAccess of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentHIV drug resistance acquired through superinfectionAssessing predicted HIV-1 replicative capacity in a clinical settingRecombination accelerates adaptation on a large-scale empirical fitness landscape in HIV-1Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinNovel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeDifferential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsImmune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruptionPhenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesEvolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.Time trends in primary HIV-1 drug resistance among recently infected persons.Exploring the complexity of the HIV-1 fitness landscape.Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase.Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.A case-based reasoning system for genotypic prediction of HIV-1 co-receptor tropism.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensPredicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational methodPractical applications of viral fitness in clinical practice.Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismMacaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesCoreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
P50
Q22242814-9859D460-4107-41B8-B72D-7C97E8D27C30Q24538985-73DBF872-A75C-43BD-B771-A3E5C5820313Q24561905-34E4B4EB-8E2E-4220-B84B-F455CDCF1CC5Q24645530-A545B0F4-07A2-49CE-95E0-2EEA29F78D9EQ24814874-56105786-077E-4724-A78D-E7D7BB889DD3Q28264308-81A096D1-6082-4C05-8E0B-635911AC2530Q28477801-D865A4F2-A421-4362-9F62-FA0CC26DD61CQ28540044-869AD37D-B610-40D3-87A3-7211F434D6B1Q28544845-07B5028F-C9E6-4AAA-91DC-811B18D24AFEQ28743092-DE5B3252-0067-48F8-9364-79B71DF15CB1Q30564087-B8E9728A-197E-479D-991B-2B1486465259Q31033895-5177DE63-E4B2-42F1-8245-CE2AEA025410Q33417195-DA31BF0E-E7A7-4099-9132-1534257EEC7CQ33533628-2043B007-F20B-4F89-9C3F-4CC9A05AEE84Q33535654-B847CC63-B37B-4A5B-BF60-6A0DD9806848Q33571825-4B121FA5-C79D-4446-A081-1793E5E0C787Q33685141-4A46AF75-0D2B-4182-98FF-68060901AE7CQ33745356-29316592-5F55-472D-B7DC-6CCBB3AEE61AQ33780566-5C4D8B60-0F8A-4D6F-BC40-CB8E19159256Q33780595-D5036DAB-7D99-4A67-A9B5-D0128808CE12Q33810849-5F7637B2-094F-48FF-AAF3-CF4E426A7679Q33911935-E4EA7C8C-6717-42E8-AB0B-A07C44206E24Q33931265-013D2284-B2BF-4A70-98E6-CF843BE8E9E9Q33951977-4A570148-4096-4F19-B8CA-154308454497Q34009945-FF1137BD-9F00-4D73-A206-42623C70E543Q34136709-BDF790FA-388F-4ECD-994B-1DD204D80ED8Q34192888-6855D486-87FE-4A44-9769-DC358EAE4296Q34288751-D8FAE975-6C12-4F40-A428-706F55D937ECQ34342079-6BE80A36-9357-45C6-A53C-6399F3620F03Q34405065-F45CA68A-1EBA-431A-AF1A-4BD0D8F0B199Q34651668-2F4A423F-66B8-484E-B474-6385898BB6B9Q34823507-5E943B0A-9013-488E-908F-10CE58D4E185Q35004847-55F61502-7EF8-4B8D-B51B-C20677714AFBQ35124761-341864CD-D570-483A-A44E-BF647896969AQ35160670-784EB5FB-EB94-4916-B807-9BB268C46468Q35547693-9FB61D6F-F913-434C-9713-2F9BE06DAEACQ35635933-23F7729A-5EE2-4663-953A-A650A9DEBC88Q35857254-88198BBC-0439-410C-B4D4-1C34E99BF56AQ35947561-DE7B53E3-DC0E-46FB-A48F-0380897A86B9Q36099376-E91BCE0C-CC7B-4537-AF12-0227E0F81121
P50
name
Christos J Petropoulos
@en
type
label
Christos J Petropoulos
@en
prefLabel
Christos J Petropoulos
@en